Emergent BioSolutions Inc. Common Stock (EBS)

EBS earnings call for the period ending December 31, 2024.

For the first quarter, Emergent forecasted revenue in the range of $200 million to $240 million, lower than an analyst estimate of $279 million.

U.S. stocks plunged Tuesday as President Donald Trump‘s tariffs on key trade partners came into effect, prompting retaliatory measures and intensifying global trade tensions.

Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics.

Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%, down from 50.9% in January. 

Stocks recovered on Friday, with all three major indexes in the green, as the tech sector bounced back from Thursday's losses with NVIDIA Corp. (NASDAQ:NVDA) up 1.37% and Tesla, Inc. (NASDAQ:TSLA)

UN calls for evidence-based, human rights-focused approach to drug policies, declaring the failed war on drugs needs to be abandoned. Urges transformative change and adoption of International Guidelines on Human Rights and Drug Policy.

The week kicks off amidst significant market movements shaped by geopolitical and policy developments.

EBS earnings call for the period ending September 30, 2024.

The U.S. overdose crisis and its racial disparities were overlooked in the election, as Black and Indigenous Americans face rising death rates.

Emergent BioSolutions stock rises on mixed Q3 results, improved 2024 guidance, and news of a new trial for mpox treatment in Africa led by the CDC.